Immucell vs Rantizo
Immucell is the larger business, with $27.6m of revenue in fiscal 2025 against $12.9m for Rantizo (2.1 times as much). Rantizo grew faster (16.6% against 4.3%). Immucell kept more of each dollar of sales as profit: a net margin of -3.8% against -22.6%. Rantizo carries less debt relative to equity (0.0% against 33.6%).
| Latest fiscal year | ImmucellICCC, 2025 | RantizoRNTZ, 2025 |
|---|---|---|
| Revenue | $27.6m | $12.9m |
| Revenue growth | 4.3% | 16.6% |
| Net income | −$1.0m | −$2.9m |
| Operating margin | 6.0% | -19.6% |
| Net margin | -3.8% | -22.6% |
| Return on equity | -3.8% | -40.2% |
| Free cash flow | $1.2m | −$5.6m |
| Cash | $3.8m | $732,000 |
| Total debt | $9.1m | $0 |
| Debt to equity | 33.6% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 73 | — |
| Market value | $95.8m | $68.4m |
| Price vs our value range | Above our value range | — |
| Moat score | 34 (Weak) | — |
| Insider trades, 12 months | 8 buys, 0 sales | 0 buys, 0 sales |